

PROOF OF IMMUNIZATION COMPLIANCE

Louisiana R.S. 17:170/Schools of Higher Learning

Student Health Services: P.O. Box 43692 · Lafayette, LA 70504-3692 · Phone: 337-482-1293 · Fax: 337-482-1872

You must either have a physician or health care provider complete documentation of Immunizations, or submit the Universal Certificate of Immunizations provided by Louisiana Department of Health, Office of Public Health. If you have not been immunized for all of the required diseases, you may request an exemption by completing the Exemption Request form. The Tuberculosis Screening Questionnaire cannot be waived and must be completed.

	Name:	ULID:				
STUDENT	Address:	Start Term:				
	Date of Birth: Phone:	Email:				
	Enrollment Status: (Check ALL that apply) □ Undergraduate □ Graduate Student □ Transfer Student □ Dual Enrollment Student □ Re-entry Student □ Online Student	Class: □Freshman				
REQUI	RED IMMUNIZATIONS					
MUST BE COMPLETED, SIGNED AND STAMPED BY HEALTHCARE PROVIDER	MMR (Measles, Mumps and Rubella) Two doses at least 28 days apart. First dose after 12 months of age. May First Dose: or Titer: Second Dose: Results:					
	MENINGITIS One dose at 16 years of age or older. Quadrivalent Vaccine A, C, Y, W-135	TETANUS One of below doses. Must be within the last 10 years.				
표	Last Dose:	Last Dose:				
PLE EAL	Choose one: Menactra Menveo	Choose one: TD TDAP				
BE COM						
UST	Provider Signature					
STA	Address					
	City, State, Zip					
	Phone	Provider Stamp Here				

Refer to Student Health Services website for instructions on how to submit forms.

PLEASE READ ENTIRE FORM CAREFULLY!

TUBERCULOSIS SCREENING QUESTIONNAIRE



(To be completed by ALL Students BEFORE registration at UL Lafayette)
THIS FORM CANNOT BE WAIVED!

FAILURE TO COMPLETE THIS FORM AND SUBMIT TO STUDENT HEALTH SERVICES WILL RESULT IN AN IMMUNIZATION HOLD ON YOUR ACCOUNT AND WILL PREVENT YOU FROM REGISTERING FOR CLASSES

Student Health Services: P.O. Box 43692, Lafayette, LA 70504-3692 • Phone: 337-482-1293 • Fax: 337-482-1872 • Email: immunizations@louisiana.edu

Name:	f-			DOB	};		JLID:		
preventionIf your TulTo avoid ofAnswer th	ette requires ALL enrolle n and control of Tuberculo berculosis Screening Que delays in receiving your l-	osis on campus. estionnaire is PC 20 and/or being ening completely	SITIVE (answe able to enroll in and accurately	ring YES to any your preferred of Misrepresentat	of the questions below classes, complete this ion of information coul	v), further testing screening as so d jeopardize you	r health and the health of others	thy process.	
Please answe	er <u>YES</u> or <u>NO</u> to the f	iollowing questi	ons:						
1. Have you	u ever had close co	ntact with p	ersons know	wn or suspe	cted to have acti	ve Tuberculo	osis disease?	□ Yes	□ No
2. Were you	u born in one of the	countries o	r territories	listed BELO	W that have a hi	gh incidence	of active TB disease?	□ Yes	□ No
Angola Azerbaijan Bangladesh Belarus Botswana Brazil	Cambodia Cameroon Central African Republic Chad China Congo	Ethiopia Ghana Guinea-Bissau India Indonesia Kazakhstan	Kenya Korea Kyrgyzstan Lesotho Liberia Malawi	Moldova Mozambique Myanmar Namibia Nigeria Pakistan	Papua New Guinea Peru Philippines Russian Federation Sierra Leone Somalia	South Africa Swaziland Tajikistan Tanzania Thailand Uganda	Ukraine Uzbekistan Viet Nam Zambia Zimbabwe		
	ce of TB disease? (angn	□ Yes	□ No
	u been a resident a lities, and homeles			risk congreg	ate settings (e.g	., correction	al facilities, long-term	□ Yes	□ No
5. Have you	been a volunteer	or health car	e worker w	ho served cl	ients who are at	increased ri	sk of active TB disease?	□ Yes	□ No
M. tubero	Health Organization Global Hea	active TB di	sease: med	dically under the 2019. Countries	served, low-inco	me, or abusi	ng drugs or alcohol?) population. For future updates,	□ Yes	□ No
	www.who.int/tb/country/en/. Ut htrol (www.cdc.gov/tb/publication			elines of the America	an College Health Associat	ion (www.acha.org)	and the US Center	-	
If the answe	r to <u>ALL</u> of the above que	estions is NO, no	o further testing	or action is requ	uired except to turn for	m in to SHS.			
beginning cla		re provider comp	lete the attache	ed TB Risk Asse	ssment and testing for	m and return it to	Test (TST/PPD) or blood test pri o Student Health Services.	or to	

Turn completed form into Student Health Services by mail, via fax, in person, or email to: immunizations@louisiana.edu prior to the start of school. This questionnaire can also be answered electronically via the patient portal. Patient portal is accessable through ULINK using your ULID and password. Any detailed information about how to complete this form or, how to get follow up testing can be explained via email or at Student Health Services.

2. If you have received treatment for active TB disease, you will need to provide proper documentation of treatment to Student Health Services prior to attending class.

1. PPD (Mantoux) Skin test read and documented in millimeters of induration or IGRA blood test results. Both must be within the last 12 months.



Tuberculosis Risk Assessment

*** To be completed by a Health Care Provider ***

FAILURE TO COMPLETE THIS FORM AND SUBMIT TO STUDENT HEALTH SERVICES WILL RESULT IN AN IMMUNIZATION HOLD ON YOUR ACCOUNT AND WILL PREVENT YOU FROM REGISTERING FOR CLASSES.

Name:	DOB: _		Date:	
1. Does the student have signs or symptoms of active	tuberculosis disease?	Yes or No		¥°
If <u>Yes</u> , proceed with additional evaluation to If <u>No</u> , proceed to options 2 or 3 listed below.		or seek appropria	ate treatment.	
2. Tuberculin Skin Test (TST) - TST recorded as acti	ual millimeters of indur	ation. Recommer	ded interpretation	below. Base results on risk factors
Date given:/ LFA / RFA	Health Care Pro	vider signature		
Date read:/				
Results:mm induration	Interpretation:	Positive or 1	legative	
TST interpretation guidelines:				
>5 mm is positive:				
 Recent close contacts of an individual with infectious TE 				
 Persons with fibrotic changes on a prior chest x-ray, cor Organ transplant recipients and other immunosuppresse HIV-infected persons 			mg/d of prednisone for	>1 month.)
>10 mm is positive:				
Recent arrivals to the U.S. (< 5 years) from high prevale A leasting days uses. Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arrivals to the U.S. (< 5 years) from high prevale Recent arriv	ence areas or who resided in	one for a significant a	amount of time	
 Injection drug users Mycobacteriology laboratory personnel 				
Residents, employees, or volunteers in high-risk congre	gation settings			
Persons with medical conditions that increase the risk of				
(leukemias and lymphomas, cancers of the head, neck o >15 mm is positive:	or lung), gastrectomy or jejur	ioileal bypass and we	ight loss at least 10% b	below ideal body weight.
Persons with no known risk factors for TB, except for test	sting programs required by la	w/regulations, who w	ould not otherwise be t	tested.
3. Interferon Gamma Release Assay (IGRA) – recom	nmended If previous TS	ST positive		
Date obtained: Circle specific Results: Positive or Negative	ic test: QuantiFERON	-Gold T-SPC	T	
*Must provide copy of lab result or verified lab result	on official letterhead o	r government issu	ued document.	
IF TST AND IGRA TEST COME BACK POSITIVE, EVALUATION AND CHEST X-RAY. A letter of clean				IC HEALTH UNIT FOR MEDICAL
	, , , , , , , , , , , , , , , , , , , ,			
Printed name of clinical personnel evaluating stude	ent:			
Signature of evaluating healthcare provider:				Date:
Fax form and documents to (337)482-1872 or scan and	d email to immunization	s@louisiana.edu	prior to starting se	emester at UL Lafayette.
Medical office stamp required here:				